Results 211 to 220 of about 60,310 (240)

Neuropeptide Y receptor antagonists in obesity

Expert Opinion on Investigational Drugs, 1997
Neuropeptide Y (NPY) is a 36 amino acid amidated peptide with high sequence homology to the endocrine peptides, peptide YY (PYY) and pancreatic polypeptide (PP). They appear to interact with a family of receptors that possess high affinity for one or more of these peptides.
Donald R. Gehlert, Philip Arthur Hipskind   +1 more
openaire   +3 more sources

Intracellular Trafficking of Neuropeptide Y Receptors

2015
The multireceptor multiligand system of neuropeptide Y receptors and their ligands is involved in the regulation of a multitude of physiological and pathophysiological processes. Specific expression patterns, ligand-binding modes, and signaling properties contribute to the complex network regulating distinct cellular responses.
Annette G. Beck-Sickinger, Karin Mörl
openaire   +2 more sources

Dental pulp fibroblasts express neuropeptide Y Y1 receptor but not neuropeptide Y

International Endodontic Journal, 2010
Killough SA, Lundy FT, Irwin CR. Dental pulp fibroblasts express neuropeptide Y Y1 receptor but not neuropeptide Y. International Endodontic Journal, 43, 835–842, 2010.AbstractAim  To investigate whether dental pulp fibroblasts express neuropeptide Y (NPY) and NPY‐Y1 in vitro and to determine the effects of the cytokines including interlukin‐1β (IL‐1β)
Killough, S. A., Lundy, F. T., Irwin, C. R.   +2 more
openaire   +4 more sources

Neuropeptide y receptor in bovine hippocampus is a Y2 receptor

Life Sciences, 1992
[125I]NPY bound to a single class of saturable binding sites on bovine hippocampus membranes with a KD of 0.1 mM and Bmax of 165 fmol/mg of protein. The rank order of potency of NPY fragments and other structurally related peptides to inhibit [125I]NPY binding was: PYY greater than or equal to NPY much greater than BPP greater than or equal to APP and ...
Terry D. Hexum, Wei Li, Richard G. MacDonald   +2 more
openaire   +3 more sources

Neuropeptide Y receptor antagonists

Expert Opinion on Therapeutic Patents, 1999
On the basis of pharmacological observations, neuropeptide Y (NPY) has been implicated to be involved in numerous physiological functions. Preliminary results suggest a wide therapeutic utility for NPY antagonists in disorders such as anxiety, appetite stimulation, obesity, alcohol intake, hypertension, and regulation of coronary tone. This review will
openaire   +2 more sources

GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists

European Journal of Pharmacology, 1998
GR231118, BW1911U90, Bis(31/31')[[Cys31, Trp32, Nva34] neuropeptide Y(31-36)] (T-190) and [Trp-Arg-Nva-Arg-Tyr]2-NH2 (T-241) are peptide analogs of the C-terminus of neuropeptide Y that have recently been shown to be antagonists of the neuropeptide Y Y1 receptor.
Deborra E Mullins, Ling Xia, Mario Guzzi, Eric M. Parker, Gitali Mukhopadhyay, Z. Tao, Fozia Hamud, Melissa A.B. Tice, Robert E. Burrier, Brian G. Salisbury, Ambikaipakan Balasubramaniam, Mark Stephen Rudinski, Carol K Babij   +12 more
openaire   +3 more sources

Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues

Peptides, 2002
mRNA encoding the human NPY Y1 and NPY Y2 receptors were detected in cerebral, meningeal, and coronary arteries using reverse transcriptase-polymerase chain reaction (RT-PCR). In addition, the trigeminal and superior cervical ganglia were positive for both receptors.
Jonas Ekstrand, Torun Nilsson, Sebastian Möller, Lars Edvinsson, Susanne Nyström, Rolf Uddman   +5 more
openaire   +3 more sources

Dihydropyridine Neuropeptide Y Y1 Receptor Antagonists

Bioorganic & Medicinal Chemistry Letters, 2002
Dihydropyridine 5a was found to be an inhibitor of neuropeptide Y(1) binding in a high throughput (125)I-PYY screening assay. Structure-activity studies around certain portions of the dihydropyridine chemotype identified BMS-193885 (6e) as a potent and selective Y(1) receptor antagonist.
Marc Bruce, Eric M. Parker, Jennifer A. Stanley, Ildiko Antal-Zimanyi, Meredith Arcuri, Graham S. Poindexter, Ivo Monkovic, Rachel T. McGovern, Gail K. Mattson, Michael R. Kozlowski, Scott W. Martin, Astrid A. Ortiz, Larry Iben, Karen Leboulluec   +13 more
openaire   +3 more sources

Modulation of neuropeptide Y receptors for the treatment of obesity

Expert Opinion on Therapeutic Patents, 2009
Neuropeptide Y (NPY) has been demonstrated to have critical roles in the physiological control of appetite and energy homeostasis through NPY Y1, Y2, Y4 and Y5 receptors. A number of synthetic ligands for NPY receptor subtypes have been developed to date, with Y5 receptor antagonists and Y2 and Y4 receptor agonists advancing into clinical trials.A ...
Nagaaki Sato, Yoshio Ogino, Makoto Ando, Satoshi Mashiko   +3 more
openaire   +3 more sources

Neuropeptide Y Receptor in Vascular Smooth Muscle

Journal of Neurochemistry, 1991
Abstract: 125I‐Bolton‐Hunter (125I‐BH) neuropeptide Y (NPY) was used to identify specific high‐affinity NPY binding sites in porcine aortic smooth muscle membrane fractions and to characterize the binding sites in comparison with those in porcine hippocampal membrane fractions.
Yasushi Shigeri, Masafumi Fujimoto, Shin-ichi Mihara   +2 more
openaire   +3 more sources